OBJECTIVE: To evaluate the efficacy and safety of Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation (BMT) with unrelated donor for @entity2590 . METHODS: Six @entity1 received chemotherapy regimen of @entity1863 (Bu) and @entity786 (CY) before allogeneic BMT (Bu 4 mg . kg(-1) . d(-1), -7 d - -4 d, CY 60 mg . kg(-1) . d(-1), -3 d - -2 d). @entity6051 mofetil combined with @entity205 and @entity1499 was used for prevention of @entity2132 after transplantation. Lipo prostaglandin E(1)was used in prophylactic regimen for @entity5501 . RESULT: Neutrophil count began to be higher than 0.5 x 10(9)/Lat the 18th day after BMT. Platelet count began to be higher than 20 x 10(9)/Lat the 21st day after BMT. Disease-free survival in the six @entity1 was 27 months. CONCLUSION: Bu-CY(2) conditioning regimen on allogeneic bone marrow transplantation with unrelated donor is an effective therapy for @entity1 with @entity2590 .

[Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['acute graft-versus-host disease'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['hepatic veno-occlusive disease'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity6051 :: ('CHEBI:168396', 'Chemical') :: ['Mycophenolate']
@entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndrome']
